Effect of Baseline HIV Disease Parameters on CD4+ T Cell Recovery After Antiretroviral Therapy Initiation in Kenyan Women

Background Antiretroviral therapy (ART) for HIV infection reconstitutes the immune system and improves survival. However, the rate and extent of CD4+ T cell recovery varies widely. We assessed the impact of several factors on immune reconstitution in a large Kenyan cohort. Methodology/Principal Findings HIV-infected female sex workers from a longitudinal cohort, with at least 1 year of pre-ART and 6 months of post-ART follow-up (n = 79), were enrolled in the current study. The median pre-ART follow-up was 4,040 days. CD4 counts were measured biannually and viral loads where available. The median CD4 count at ART initiation was 180 cells/ul, which increased to 339 cells/ul at the most recent study visit. The rate of CD4+ T cell increase on ART was 7.91 cells/month (mean = 13, range −25.92 to 169.4). LTNP status prior to ART initiation did not associate with the rate of CD4 recovery on ART. In univariate analyses, associations were observed for CD4 recovery rate and duration of pre-ART immunosuppression (r = −0.326, p = 0.004) and CD4 nadir (r = 0.284, p = 0.012). In multivariate analysis including age, CD4 nadir, duration of HIV infection, duration of pre-ART immunosuppression, and baseline viral load, only CD4 nadir (p = 0.007) and not duration of immunosupression (p = 0.87) remained significantly associated with the rate of CD4 recovery. Conclusions/Significance These data suggest that prior duration of immune suppression does not predict subsequent recovery once ART is initiated and confirm the previous observation that the degree of CD4 depletion prior to ART initiation is the most important determinant of subsequent immune reconstitution.

[1]  M Egger,et al.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. , 1999, JAMA.

[2]  M. Lindegren,et al.  Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Dersimonian,et al.  Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. , 2003, Journal of acquired immune deficiency syndromes.

[4]  Jeffrey N. Martin,et al.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.

[5]  J. Benito,et al.  Differential Upregulation of CD38 on Different T-Cell Subsets May Influence the Ability to Reconstitute CD4+ T Cells Under Successful Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.

[6]  A. Flahault,et al.  Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. , 2005, The Journal of infectious diseases.

[7]  D. Podzamczer,et al.  Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  R. Cheynier,et al.  Naïve T-Cell Depletion Related to Infection by X4 Human Immunodeficiency Virus Type 1 in Poor Immunological Responders to Highly Active Antiretroviral Therapy , 2006, Journal of Virology.

[9]  S. Kalams,et al.  Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. , 2006, The Journal of infectious diseases.

[10]  R. Haubrich,et al.  Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. , 2006, The Journal of infectious diseases.

[11]  Anne M Johnson,et al.  Changes in the risk of death after HIV seroconversion compared with mortality in the general population. , 2008, JAMA.

[12]  M. Muñoz-Fernández,et al.  Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency. , 2008, The Journal of infection.

[13]  A. Fauci,et al.  Universal voluntary testing and treatment for prevention of HIV transmission. , 2009, JAMA.

[14]  Giulia Marchetti,et al.  The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Lederman,et al.  Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. , 2009, The Journal of infectious diseases.

[16]  Stephen R Cole,et al.  Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies , 2009, The Lancet.

[17]  R. Shafer,et al.  Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Michael J Silverberg,et al.  Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.

[19]  B. Agan,et al.  CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.